Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Acknowledgment of Support

This activity is supported by educational grants from Karyopharm Theraputics, Inc., Oncopeptides, Inc., and Takeda Oncology.

Oncology Briefings®: Highlighting New Multiple Myeloma Treatments for the Oncology Nurse

Release Date: December 23, 2020
Expiration Date: December 23, 2021

Activity Overview

This online activity is designed to provide oncology nurses with a concise and focused overview of current and emerging therapies for the treatment of patients with multiple myeloma (MM), the adverse events associated with these treatments and their management strategies, and the role of the oncology nurse both in the multidisciplinary care team and as a liaison between physicians and patients/caregivers. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Karyopharm Theraputics, Inc., Oncopeptides, Inc., and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is intended for hematology/oncology nurses involved in the treatment of patients with MM.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Understand the impact of disease-specific factors, treatment history, and risk stratification on therapy decisions using novel agents or combinations in MM
• Assess the efficacy and safety profile for novel agents and combinations in multiple lines of care among patients with MM
• Determine treatment-related toxicities associated with the wide diversity of new therapeutic strategies for MM to maximize clinical outcomes
• Apply knowledge of evidence-based toxicity profile of novel agents for MM to facilitate effective counselling, patient education, and empowerment

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Laura Zitella, MS, RN, ACNP-BC, AOCN
Laura Zitella, MS, RN, ACNP-BC, AOCN
Nurse Practitioner
Associate Clinical Professor
University of California, San Francisco
San Francisco, CA

Disclosures: Laura Zitella, MS, RN, ACNP-BC, AOCN has no relevant financial relationships with commercial interests.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By